In the Claims

1. (Currently amended) ~~Methylene urea derivatives~~ A compound of formula I

A-D-B (I)

wherein

D is a bivalent methylene urea moiety, or a derivative therof,

A is a unsubstituted or substituted moiety of up to 40 carbon atoms of the formula: -L-(M-L')$_\alpha$, where L is a 5, 6 or 7 membered cyclic structure, ~~preferably~~ selected from the group consisting of aryl, heteroaryl, arylene and heteroarylene, bound directly to D, L' comprises an optionally substituted cyclic moiety having at least 5 members, ~~preferably~~ selected from the group consisting of aryl, heteroaryl, aralkyl, cycloalkyl and heterocyclyl, M is a bond or a bridging group having at least to one atom, α is an integer of from 1-4; and each cyclic structure of L and L' contains 0-4 members of the group consisting of nitrogen, oxygen and sulfur, wherein L' is ~~preferably~~ substituted by at least one substituent selected from the group consisting of –SO$_\beta$R$_x$, -C(O)R$_x$ and –C(NR$_y$)R$_z$

B is a substituted or unsubstituted, up to tricyclic aryl or heteroaryl moiety of up to 30 carbo atoms, ~~preferably of up to 20 carbon atoms~~, comprising at least one 5-, 6-, or 7-membered cyclic structure, ~~preferably~~ a 5- or 6-membered cyclic structure, bound directly to D containing 0-4 members of the group consisting of

nitrogen, oxygen and sulfur, wherein said cyclic structure directly bound to D is ~~preferably~~ selected from the group consisting of aryl, heteroaryl and heterocyclyl, R_y is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally halosubstituted, up to per halo,

R_z is hydrogen or a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

R_x is R_z or NR_aR_b, where R_a and R_b are

a) independently hydrogen, a carbon based moiety of up to 30 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen, or

$-OSi(R_f)_3$ where R_f is hydrogen or a carbon based moiety of up to 24 carbon atoms optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, hydroxy and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;

or

b) R_a and R_b together form a 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O, or a substituted 5-7 member heterocyclic structure of 1-3 heteroatoms selected from N, S and O substituted by halogen, hydroxy or carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen; or

c) one of R_a or R_b is -C(O)-, a C_1-C_5 divalent alkylene group or a substituted C_1-C_5 divalent alkylene group bound to the moiety L to form a cyclic structure with at least 5 members, wherein the substituents of the substituted C_1-C_5 divalent alkylene group are selected from the group consisting of halogen, hydroxy, and carbon based substituents of up to 24 carbon atoms, which optionally contain heteroatoms selected from N, S and O and are optionally substituted by halogen;
where B is substituted, L is substituted or L' is additionally substituted, the substituents are selected from the group consisting of halogen, up to per-halo, and W_γ, where γ is 0-3; wherein each W is independently selected from the group consisting of -CN, $-CO_2R$, $-C(O)NR^5R^5$, $-C(O)-R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-NR^5R^5$, $-NR^5C(O)OR^5$, $-NR^5C(O)R^5$, -Q-Ar, and carbon based moieties of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents independently selected from the groups consisting of -CN, $-CO_2R$, $-C(O)NR^5R^5$, $-C(O)-R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-NR^5R^5$, $-NR^5C(O)OR^5$, $-NR^5C(O)R^5$ and halogen up to

per-halo; with each R^5 independently selected from H or a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by halogen, wherein Q is -O-, -S-, -N(R^5)-, -$(CH_2)_\beta$, -C(O)-, -CH(OH)-, -$(CH_2)_\beta$-, -$(CH_2)_\beta$S-, -$(CH_2)_\beta$N(R^5)-, -O$(CH_2)_\beta$-CHHal-, -CHal$_2$-, -S-(CH_2).- and -N(R^5)$(CH_2)_\beta$- where β = 1-3, and Hal is halogen; and Ar is 5- or 6-member aromatic structure containing 0-2 members selected from the group consisting of nitrogen, oxygen and sulfur, which is optionally substituted by halogen, up to per-halo, and optionally substituted by Zδ1 wherein δ1 is 0 to 3 and each Z is independently selected from the group consisting-CN, -CO_2R^5, -C(O)NR^5R^5, -C(O)-R^5, -NO_2, -OR^5, -SR^5, -SO_2R^5, -SO_3H, -NR^5R^5, -NR^5C(O)OR^5, -NR^5C(O)R^5, and a carbon based moiety of up to 24 carbon atoms, optionally containing heteroatoms selected from N, S and O and optionally substituted by one or more substituents selected from the group consisting of -CN, -CO_2R^5, -C(O)NR^5R^5, -C(O)-R^5, -NO_2, -OR^5, -SR^5, -SO_2R^5, -SO_3H, -NR^5R^5, -NR^5C(O)OR^5, -NR^5C(O)R^5, and ~~the~~ pharmaceutically acceptable derivatives, salts and solvates thereof.

2. (Currently amended) ~~Methylene urea derivative~~ The compound according to claim 1, ~~characterised in that~~ wherein each M independently from one another represents a bond OR is a bridging group, selected from the group consisting of $(CR^5R^5)_h$, or $(CHR^5)_h$-Q-$(CHR^5)_i$, wherein

Q is selected from a group consisting of O, S, N-R^5, $(CHal_2)_i$,

$(O\text{-}CHR^5)_j$, $(CHR^5\text{-}O)_j$, $CR^5{=}CR^5$, $(O\text{-}CHR^5CHR^5)_j$, $(CHR^5CHR^5\text{-}O)_j$, C=O, C=S, $C{=}NR^5$, $CH(OR^5)$, $C(OR^5)(OR^5)$, $C(=O)O$, $OC(=O)$, $OC(=O)O$, $C{=}O)N(R^5)C(=O)$, $OC(=O)N(R^5)$, $N(R^5)C(=O)O$, $CH{=}N\text{-}NR^5$, $OC(O)NR^5$, $NR^5C(O)O$, S=O, SO_2, SO_2NR^5 und NR^5SO_2, wherein

R^5 is in each case independently selected from the meanings given above, ~~preferably~~ hydrogen, halogen, alkyl, aryl, aralkyl,

h, i are independently from each other 0, 1, 2, 3, 4, 5, or 6, ~~preferably 0, 1, 2 or 3,~~ and

j is 1, 2, 3, 4, 5 or 6~~, preferably 0, 1, 2 or 3~~.

3. (Currently amended) ~~Methylene urea derivative~~ The compound according to claim 1, selected from the compounds of formula II,



II

wherein

Ar^1, Ar^2 are selected independently from one another from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two hetero atoms, independently selected from N, O und S,

R^6, R^7 are independently selected from a the meanings given for R^8, R^9 and R^{10}, or
R^6 and R^7 together form a carbocyclic residue comprising 3 to 7 carbon atoms or a heterocyclic residue comprising 1, 2 or 3 hetero atoms, selected from the group consisting of O, N and S, and 2 to 6 carbon atoms, said carbocyclic or heterocyclic residue being unsubstituted or comprising 1, 2 or 3 substituents, selected from the meanings given for R^8, R^9 and R^{10},

E, G, M, Q and U are selected, independently from one another, from carbon atoms and nitrogen atoms, with the proviso that one or more of E, G, M, Q and U are carbon atoms and that X is bonded to a carbon atom,

R^8, R^9 and R^{10} are independently selected from ~~a~~ the group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nNR^{11}(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kOR^{11}$, $(CH_2)_nNR^{11}(CH_2)_kOR^{12}$, $(CH_2)_nCOOR^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^8CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_nCH$=N-R^{11}, $(CH_2)_nOC(O)NR^{11}R^{12}$, $(CH_2)_nNR^{11}COOR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^8$, $(CH_2)_nN(R^{11})$, $C(R^{13})HCOR^8$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^8$,

$(CH_2)_nN(R^8)CH_2CH_2NR^{12}R^8$, CH=CHCOOR^{13}, CH=CHCH$_2$NR^{11}R^{12}, CH=CHCH$_2$NR^{11}R^{12}, CH=CHCH$_2$OR^{13}, $(CH_2)_nN(COOR^{13})COOR^{14}$, $(CH_2)_nN(CONH_2)COOR^{13}$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{13})COOR^{14}$, $(CH_2)_nN(CH_2CONH_2)COOR^{13}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{14}$, $(CH_2)_nCHR^{13}COOR^{14}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$ and $(CH_2)_nNCO$, wherein

R^{11}, R^{12} are independently selected from a the group consisting of H, A, $(CH_2)_mAr^3$ and $(CH_2)_m$Het, or in NR^{11}R^{12},

R^{11} and R^{12} form, together with the N-atom they are bound to, a 5-, 6- or 7- membered heterocyclus which optionally contains 1 or 2 additional hetero atoms, selected from N, O and S,

R^{13}, R^{14} are independently selected from a the group consisting of H, Hal, A, $(CH_2)_mAr^4$ and $(CH_2)_m$Het,

A is selected from the group consisting of alkyl, alkenyl, cycloalkyl, alkylenecycloalkyl, alkoxy, alkoxyalkyl and saturated heterocyclyl,

Ar^3, Ar^4 are independently from one another aromatic hydrocarbon residues comprising 5 to 12 ~~and preferably 5 to 10~~ carbon atoms which are optionally substituted by one or more substituents, selected from a the group consisting of A, Hal, NO_2, CN, OR^{15}, NR^{15}R^{16}, COOR^{15}, CONR^{15}R^{16}, NR^{15}COR^{16}, NR^{15} CONR^{15}R^{16}, NR$^{16}SO_2$A, COR^{15}, SO_2R^{15}R^{16}, $S(O)_0$A

and $OOCR^{15}$,

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from a the group consisting of A, Hal, NO_2, CN, OR^{15}, $NR^{15}R^{16}$, $COOR^{15}$, $CONR^{15}R^{16}$, $NR^{15}COR^{16}$, $NR^{15}CONR^{15}R^{16}$, $NR^{16}SO_2A$, COR^{15}, $SO_2R^{15}R^{16}$, $S(O)_uA$ and $OOCR^{15}$,

R^{15}, R^{16} are independently selected from a the group consisting of H, A, and $(CH_2)_mAr^6$, wherein

Ar^6 is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from a the group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH_2 and CF_3,

k, n and m are independently of one another 0, 1, 2, 3, 4, or 5;

X represents a bond or is $(CR^{11}R^{12})_h$, or $(CHR^{11})_n$-Q-$(CHR^{12})_i$, wherein

Q is selected from a the group consisting of O, S, N-R^{15}, $(CHal_2)_j$, $(O\text{-}CHR^{18})_j$, $(CHR^{18}\text{-}O)_j$, $CR^{18}{=}CR^{19}$, $(O\text{-}CHR^{18}CHR^{19})_j$, $CHR^{18}CHR^{19}\text{-}O)_j$, C=O, C=S, $C{=}NR^{15}$, $CH(OR^{15})$, $C(OR^{15})(OR^{20})$, C(=O)O, OC(=O), OC(=O)O, $C(=)N(R^{15})$, $N(R^{15})C(=O)$, $OC(=O)N(R^{15})$, $N(R^{15})C(=O)O$, CH=N-O, $CH{=}N\text{-}NR^{15}$, $OC(O)NR^{15}$, $NR^{15}C(O)O$, S=O, SO_2, SO_2NR^{15} und $NR^{15}SO_2$, wherein

h, i are independently from each other 0, 1, 2, 3, 4, 5 or 6, and

j is 1, 2, 3, 4, 5 or 6,

Y is selected from O, S, NR^{21}, $C(R^{22})$-NO_2, $C(R^{22})$-CN and $C(CN)_2$, wherein

R^{21} is independently selected from the meanings given for R^{13}, R^{14}, and

R^{22} is independently selected from the meanings given for R^{11}, R^{12},

p, r are independently from one another 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4, ~~preferably 0, 1 or 2~~,

u is 0, 1, 2 or 3, ~~preferably 0, 1 or 2~~,

and

Hal is independently selected from ~~a~~ the group consisting of F, Cl, Br and I;

and ~~the~~ pharmaceutically acceptable derivatives, salts and solvates thereof.

4. (Currently amended) ~~Methylene urea derivative~~ The compound according to claim 1, selected from the compounds of formula IIc, IId, IIe, IIf,

IIg, IIh, IIi, IIj, IIk, IIL, IIm, IIn, IIo, IIp, IIq, IIr, IIs, IIt, IIu, IIv, IIw and IIx,



IIc



IId



IIe



IIf



IIg



IIh



IIi



IIj



IIk



IIL



IIm



IIn



IIo



IIp



IIq



IIr



IIs



IIt



IIu



IIv



IIw



IIx

wherein R^6, R^7, R^8, p, Ar^1, Y, X, R^9 and q is 0, 1, 2, 3 or 4 ~~are as defined in claim 3~~, R^{10} is ~~H or as defined in claim 3~~ selected from the group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH_2Hal, $CH(Hal)_2$, $C(Hal)_3$, NO_2, $(CH_2)_nCN$, $(CH_2)_nNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nNR^{11}(CH_2)_kNR^{11}R^{12}$, $(CH_2)_nO(CH_2)_kOR^{11}$, $(CH_2)_nNR^{11}(CH_2)_kOR^{12}$, $(CH_2)_nCOOR^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nCONR^{11}R^{12}$, $(CH_2)_nNR^{11}COR^{13}$, $(CH_2)_nNR^8CONR^{11}R^{12}$, $(CH_2)_nNR^{11}SO_2A$, $(CH_2)_nSO_2NR^{11}R^{12}$, $(CH_2)_nS(O)_uR^{13}$, $(CH_2)_nOC(O)R^{13}$, $(CH_2)_nCOR^{13}$, $(CH_2)_nSR^{11}$, CH=N-OA, CH_2CH=N-OA, $(CH_2)_nNHOA$, $(CH_2)_nCH$=N-R^{11}, $(CH_2)_nOC(O)NR^{11}R^{12}$, $(CH_2)_nNR^{11}COOR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OR^{13}$, $(CH_2)_nN(R^{11})CH_2CH_2OCF_3$, $(CH_2)_nN(R^{11})C(R^{13})HCOOR^8$, $(CH_2)_nN(R^{11})$, $C(R^{13})HCOR^8$, $(CH_2)_nN(R^{11})CH_2CH_2N(R^{12})CH_2COOR^8$, $(CH_2)_nN(R^8)CH_2CH_2NR^{12}R^8$, $CH=CHCOOR^{13}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2NR^{11}R^{12}$, $CH=CHCH_2OR^{13}$, $(CH_2)_nN(COOR^{13})COOR^{14}$, $(CH_2)_nN(CONH_2)COOR^{13}$, $(CH_2)_nN(CONH_2)CONH_2$, $(CH_2)_nN(CH_2COOR^{13})COOR^{14}$, $(CH_2)_nN(CH_2CONH_2)COOR^{13}$, $(CH_2)_nN(CH_2CONH_2)CONH_2$, $(CH_2)_nCHR^{13}COR^{14}$,

$(CH_2)_nCHR^{13}COOR^{14}$, $(CH_2)_nCHR^{13}CH_2OR^{14}$, $(CH_2)_nOCN$ and $(CH_2)_nNCO$,
and ~~the~~ pharmaceutically acceptable derivatives, salts and solvates thereof.

5. (Currently amended) ~~Methylene urea derivative~~ The compound according to claim 1, selected from the compounds (1) to (224) of table 1, the compounds (225) to (449) of table 2 and/or the compounds (450) to (672) of table 3, and ~~the~~ pharmaceutically acceptable derivatives, salts and solvates thereof.

6. (Currently amended) ~~Methylene urea derivative~~ The compound according to claim 1, selected from the compounds (673) to (758), the compounds (759) to (825) and/or the compounds (826) to (874), and ~~the~~ pharmaceutically acceptable derivatives, salts and solvates thereof.

7. (Currently amended) A medicament comprising the compound ~~Methylene urea derivative~~ according to claim 1 ~~as a medicament~~.

8. (Currently amended) ~~Methylene urea derivative~~ The compound according to claim 1 as a kinase inhibitor.

9. (Currently amended) ~~Methylene urea derivative~~ The compound according to claim 8, ~~characterized in that~~ wherein the kinases are selected from raf-kinases.

10. (Currently amended) A pharmaceutical ~~Pharmaceutical~~ composition, ~~characterised in that it contains one or more compounds~~ comprising the compound according to claim 1.

11. (Currently amended) The pharmaceutical composition according to claim ~~1~~ 10, ~~characterised in that~~ wherein it contains one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients ~~other than the compounds according to claim 1~~.

12. (Currently amended) A process ~~Process~~ for ~~the~~ manufacture of a pharmaceutical composition, ~~characterised in that~~ wherein one or more compounds according to claim 1 and one or more compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients ~~other than the compounds according to claim 1~~, ~~is~~ are processed by mechanical means into a pharmaceutical composition that is suitable as a dosage form for application and/or administration to a patient.

13. (Previously presented) Use of a compound according to claim 1 as a pharmaceutical.

14. (Previously presented) Use of a compound according to claim 1 in the treatment and/or prophylaxis of disorders.

15. (Previously presented) Use of a compound according to claim 1 for producing a pharmaceutical composition for the treatment and/or prophylaxis of disorders.

16. (Previously presented) Use according to claim 14, characterised in that the disorders are caused, mediated and/or propagated by raf-kinases.

17. (Previously presented) Use according to claim 14, characterised in that the disorders are selected from the group consisting of hyperproliferative and nonhyperproliferative disorders.

18. (Previously presented) Use according to claim 14, characterised in that the disorder is cancer.

19. (Previously presented) Use according to claim 14, characterised in that the disorder is noncancerous.

20. (Previously presented) Use according to claim 14, characterised in that the disorders are selected from the group consisting of psioarsis, arthritis, inflammation, endometriosis, scarring, Helicobacter pylori infection, Influenza A, begnin prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases.

21. (Previously presented) Use according to claim 14, characterised in that the disorders are selected from the group consisting of melanoma, brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, ovarian cancar, ovary cancer, uterine cancer, prostate cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.

22. (Previously presented) Use according to claim 14, characterised in that the disorders are selected from the group consisting of arthritis, restenosis; fibrotic disorders; mesangial cell proliferative disorders, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection,

glomerulopathies, metabolic disorders, inflammation, solid tumors, rheumatic arthritis, diabetic retinopathy, and neurodegenerative diseases.

23. (Previously presented) Use according to claim 14, characterised in that the disorders are selected from the group consisting of rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, renal disease and angiogenesis disorders.

24. (Previously presented) Use of a compound according to claim 1 as a raf-kinase inhibitor.

25. (Previously presented) Use according to claim 24, characterised in that the raf-kinase is selected from the group consisting of A-Raf, B-Raf and c-Raf1.

26. (Currently amended) A method ~~Method~~ for the treatment and/or prophylaxis of disorders, ~~characterised in that~~ wherein one or more compounds according to claim 1 is administered to a patient in need of such a treatment.

27. (Currently amended) A method ~~Method according to claim~~ 1, ~~characterised in that the one or more compounds according to claim 1 are administered~~ comprising, administering to a patient in need thereof the ~~as a~~ pharmaceutical composition according to claim 10.

28. (Currently amended) A method ~~Method~~ for the treatment and/or prophylaxis of disorders comprising, administering to a patient in need

thereof the pharmaceutical composition according to claim 10, wherein ~~according to claim 1, characterised in that~~ the disorders are caused, mediated and/or propagated by raf-kinases ~~are as defined in claim 16~~.

29. (Currently amended) A method ~~Method for the treatment~~ according to claim 28, ~~characterised in that~~ wherein the disorder is cancerous cell growth mediated by raf-kinase.

30. (Currently amended) A method ~~Method~~ for producing compounds of formula II, ~~characterised in that~~ wherein

a) a compound of formula III



III

wherein

FG is a functional group, selected from
–N=C=Y and –NH-(C=Y)-LG,
wherein Y is as defined as in claim 3 and LG is a leaving group,

is reacted

b) with a compound of IV,



IV

wherein

L^2, L^3 are independently from one another H or a metal ion, and R^6, R^7, E, G, M, Q, U, R^9, q, X, Ar^2, R^{10} and r are as defined in claim 3,

and optionally

c) isolating and/or treating the compound of formula II obtained by said reaction with an acid, to obtain the salt thereof.

31. (Previously presented) Compound of formula III,



III

wherein

FG is a functional group, selected from
–N=C=Y and –NH-(C=Y)-LG,
wherein Y is as defined as in claim 3 and LG is a leaving group.

32. (Previously presented) Compound of formula IV,



IV

wherein

L^2, L^3 are independently from one another H or a metal ion, and R^6, R^7, E, G, M, Q, U, R^9, q, X, Ar^2, R^{10} and r are as defined in claim 3.